Oncogene:鉴定出非编码RNA调控的新促癌基因

2019-01-17 佚名 生物通

胃癌是我国发病率和死亡率排名前三的恶性肿瘤,最新一项研究发现了胃癌中一个新的促癌基因KIAA1199,并对其促癌作用、下游信号通路和表达调控机制进行了深入研究,为胃癌的分子治疗提供了新的靶点。

癌是我国发病率和死亡率排名前三的恶性肿瘤,最新一项研究发现了癌中一个新的促癌基因KIAA1199,并对其促癌作用、下游信号通路和表达调控机制进行了深入研究,为胃癌的分子治疗提供了新的靶点。

近日,重庆医科大学药学院肖斌教授团队与陆军军医大学(原第三军医大学)国家免疫生物制品工程技术研究中心邹全明教授团队在肿瘤学领域权威杂志《Oncogene》(JCR 1区)在线发表了题为“The miR-29c-KIAA1199 axis regulates gastric cancer migration by binding with WBP11 and PTP4A3”的研究论文。

这一研究揭示了胃癌中一个新的促癌基因KIAA1199,其在胃癌中表达显着上调,且与胃癌的分期、淋巴结转移和预后相关;体内外实验证实,KIAA1199能够显着促进胃癌的转移和增殖。

此外,研究人员通过质谱(MS )分析和免疫沉淀(IP)技术,鉴定出与KIAA1199结合的下游蛋白为:WBP11 (WW domain binding protein 11)和PTP4A3(protein tyrosine phosphatase type IVA, member 3),而且KIAA1199能够通过活化WBP11- FGFR4-β-catenin和PTP4A3-EGFR-STAT3信号通路,调控EMT和肿瘤转移。研究还发现,KIAA1199是miR-29c-3p的靶基因,其表达受miR-29c-3p的负调控,后者在胃癌中显着低表达,能够抑制胃癌的转移和发生,且调控作用依赖于KIAA1199及下游信号通路。

这项研究有助于进一步阐明胃癌的发生与转移机制,也为胃癌的治疗提供了新的靶点。肖斌教授团队长期致力于非编码RNA在胃癌、细菌感染和慢性肾病中的调控作用研究,先后在Blood、Oncogene、Cell Death Dis 、J Infect Dis、Cancer science等权威期刊发表非编码RNA研究成果。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1677568, encodeId=cba716e7568e3, content=<a href='/topic/show?id=fa5c2e100cd' target=_blank style='color:#2F92EE;'>#促癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27100, encryptionId=fa5c2e100cd, topicName=促癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ab727554053, createdName=changhe722, createdTime=Sat Dec 07 02:43:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049130, encodeId=c8c0204913046, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Mar 25 02:43:00 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754023, encodeId=ae461e540239c, content=<a href='/topic/show?id=a67c2e10345' target=_blank style='color:#2F92EE;'>#促癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27103, encryptionId=a67c2e10345, topicName=促癌基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82e136650243, createdName=ssnine, createdTime=Sat Jul 13 03:43:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743488, encodeId=37ec1e434888b, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sat Nov 23 15:43:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373939, encodeId=aedc13e393907, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Sat Jan 19 04:43:00 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558139, encodeId=ea9f1558139e2, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Jan 19 04:43:00 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584731, encodeId=2e161584e311a, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Sat Jan 19 04:43:00 CST 2019, time=2019-01-19, status=1, ipAttribution=)]
    2019-12-07 changhe722
  2. [GetPortalCommentsPageByObjectIdResponse(id=1677568, encodeId=cba716e7568e3, content=<a href='/topic/show?id=fa5c2e100cd' target=_blank style='color:#2F92EE;'>#促癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27100, encryptionId=fa5c2e100cd, topicName=促癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ab727554053, createdName=changhe722, createdTime=Sat Dec 07 02:43:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049130, encodeId=c8c0204913046, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Mar 25 02:43:00 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754023, encodeId=ae461e540239c, content=<a href='/topic/show?id=a67c2e10345' target=_blank style='color:#2F92EE;'>#促癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27103, encryptionId=a67c2e10345, topicName=促癌基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82e136650243, createdName=ssnine, createdTime=Sat Jul 13 03:43:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743488, encodeId=37ec1e434888b, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sat Nov 23 15:43:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373939, encodeId=aedc13e393907, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Sat Jan 19 04:43:00 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558139, encodeId=ea9f1558139e2, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Jan 19 04:43:00 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584731, encodeId=2e161584e311a, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Sat Jan 19 04:43:00 CST 2019, time=2019-01-19, status=1, ipAttribution=)]
    2019-03-25 cy0324
  3. [GetPortalCommentsPageByObjectIdResponse(id=1677568, encodeId=cba716e7568e3, content=<a href='/topic/show?id=fa5c2e100cd' target=_blank style='color:#2F92EE;'>#促癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27100, encryptionId=fa5c2e100cd, topicName=促癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ab727554053, createdName=changhe722, createdTime=Sat Dec 07 02:43:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049130, encodeId=c8c0204913046, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Mar 25 02:43:00 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754023, encodeId=ae461e540239c, content=<a href='/topic/show?id=a67c2e10345' target=_blank style='color:#2F92EE;'>#促癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27103, encryptionId=a67c2e10345, topicName=促癌基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82e136650243, createdName=ssnine, createdTime=Sat Jul 13 03:43:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743488, encodeId=37ec1e434888b, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sat Nov 23 15:43:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373939, encodeId=aedc13e393907, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Sat Jan 19 04:43:00 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558139, encodeId=ea9f1558139e2, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Jan 19 04:43:00 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584731, encodeId=2e161584e311a, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Sat Jan 19 04:43:00 CST 2019, time=2019-01-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1677568, encodeId=cba716e7568e3, content=<a href='/topic/show?id=fa5c2e100cd' target=_blank style='color:#2F92EE;'>#促癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27100, encryptionId=fa5c2e100cd, topicName=促癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ab727554053, createdName=changhe722, createdTime=Sat Dec 07 02:43:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049130, encodeId=c8c0204913046, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Mar 25 02:43:00 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754023, encodeId=ae461e540239c, content=<a href='/topic/show?id=a67c2e10345' target=_blank style='color:#2F92EE;'>#促癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27103, encryptionId=a67c2e10345, topicName=促癌基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82e136650243, createdName=ssnine, createdTime=Sat Jul 13 03:43:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743488, encodeId=37ec1e434888b, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sat Nov 23 15:43:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373939, encodeId=aedc13e393907, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Sat Jan 19 04:43:00 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558139, encodeId=ea9f1558139e2, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Jan 19 04:43:00 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584731, encodeId=2e161584e311a, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Sat Jan 19 04:43:00 CST 2019, time=2019-01-19, status=1, ipAttribution=)]
    2019-11-23 d830384
  5. [GetPortalCommentsPageByObjectIdResponse(id=1677568, encodeId=cba716e7568e3, content=<a href='/topic/show?id=fa5c2e100cd' target=_blank style='color:#2F92EE;'>#促癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27100, encryptionId=fa5c2e100cd, topicName=促癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ab727554053, createdName=changhe722, createdTime=Sat Dec 07 02:43:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049130, encodeId=c8c0204913046, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Mar 25 02:43:00 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754023, encodeId=ae461e540239c, content=<a href='/topic/show?id=a67c2e10345' target=_blank style='color:#2F92EE;'>#促癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27103, encryptionId=a67c2e10345, topicName=促癌基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82e136650243, createdName=ssnine, createdTime=Sat Jul 13 03:43:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743488, encodeId=37ec1e434888b, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sat Nov 23 15:43:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373939, encodeId=aedc13e393907, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Sat Jan 19 04:43:00 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558139, encodeId=ea9f1558139e2, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Jan 19 04:43:00 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584731, encodeId=2e161584e311a, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Sat Jan 19 04:43:00 CST 2019, time=2019-01-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1677568, encodeId=cba716e7568e3, content=<a href='/topic/show?id=fa5c2e100cd' target=_blank style='color:#2F92EE;'>#促癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27100, encryptionId=fa5c2e100cd, topicName=促癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ab727554053, createdName=changhe722, createdTime=Sat Dec 07 02:43:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049130, encodeId=c8c0204913046, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Mar 25 02:43:00 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754023, encodeId=ae461e540239c, content=<a href='/topic/show?id=a67c2e10345' target=_blank style='color:#2F92EE;'>#促癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27103, encryptionId=a67c2e10345, topicName=促癌基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82e136650243, createdName=ssnine, createdTime=Sat Jul 13 03:43:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743488, encodeId=37ec1e434888b, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sat Nov 23 15:43:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373939, encodeId=aedc13e393907, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Sat Jan 19 04:43:00 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558139, encodeId=ea9f1558139e2, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Jan 19 04:43:00 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584731, encodeId=2e161584e311a, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Sat Jan 19 04:43:00 CST 2019, time=2019-01-19, status=1, ipAttribution=)]
    2019-01-19 zsyan
  7. [GetPortalCommentsPageByObjectIdResponse(id=1677568, encodeId=cba716e7568e3, content=<a href='/topic/show?id=fa5c2e100cd' target=_blank style='color:#2F92EE;'>#促癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27100, encryptionId=fa5c2e100cd, topicName=促癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ab727554053, createdName=changhe722, createdTime=Sat Dec 07 02:43:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049130, encodeId=c8c0204913046, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Mar 25 02:43:00 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754023, encodeId=ae461e540239c, content=<a href='/topic/show?id=a67c2e10345' target=_blank style='color:#2F92EE;'>#促癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27103, encryptionId=a67c2e10345, topicName=促癌基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82e136650243, createdName=ssnine, createdTime=Sat Jul 13 03:43:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743488, encodeId=37ec1e434888b, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sat Nov 23 15:43:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373939, encodeId=aedc13e393907, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Sat Jan 19 04:43:00 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558139, encodeId=ea9f1558139e2, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Jan 19 04:43:00 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584731, encodeId=2e161584e311a, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Sat Jan 19 04:43:00 CST 2019, time=2019-01-19, status=1, ipAttribution=)]

相关资讯

优秀病例:黏膜下肿瘤样胃癌一例

患者,男,50岁。因“查体发现胃占位半月”于2017年6月1日入院。

胃癌诊疗规范(2018年版)

胃癌治疗的总体策略是以外科为主的综合治疗,为进一步规范我国胃癌诊疗行为,提高医疗机构胃癌诊疗水平,改善胃癌患者预后,保障医疗质量和医疗安全,特制定本规范。本规范所称的胃癌是指胃腺癌(以下简称胃癌),包括胃食管结合部癌。

盘点2018:梁军教授:胃癌内科研究进展

2018年已成为历史,又到了我们回顾、总结、思考、展望的季节。回首过去的一年,肿瘤治疗领域发展如火如荼。这一年,免疫治疗走进了中国,各种免疫联合治疗的实践火热开展;已有靶向药物有了新的突破,新的靶向药物层出不穷。胃癌(GC)是世界范围内第五常见肿瘤并且在癌症相关死亡的第三位,在胃癌治疗领域,也发布了多项临床研究结果,这其中,有阳性结果,有阴性结果;有的能改变我们的临床实践,有的能给我们带来一点思考

CCI可作为老年胃癌患者非治愈性ESD治疗后追加外科手术决策的有用参数

近几十年来,世界范围内老年人口规模迅速增长。胃癌在日本仍然是常见的死亡原因。内镜黏膜下剥离术(ESD)是一种公认的早期胃癌(EGC)的标准治疗方法。ESD被认为是一种侵入性较小的治疗方法,与开放手术相比,可改善术后生活质量。此外,许多研究显示ESD对EGC的短期和长期疗效良好,甚至对老年患者也是如此。

Nat Commun:鉴定出人胃黏膜的蛋白质组

胃粘膜是胃壁最活跃的一层,参与食物的消化、代谢过程和胃癌的发生。从解剖学上讲,人的胃分为七个区域,但基于胞内特异性的蛋白质尚不清楚。2019年1月3日,解放军总医院第五医学中心徐建明团队在国际权威期刊Nature Communications上发表题为“region-resolved mucosa proteome ofthe human stomach”的文章,该文章以人胃黏膜样本作为研究对象,

Life Sci:喜讯|浙大转化医学院闵军霞团队在天然产物抗胃癌研究领域获得重要进展

梅、兰、竹、菊,是我国传统绘画中常见的重要题材,称为“四君子”。 竹子,不仅青翠挺拔,“劲节虚心”深为国人喜爱;同时,竹子还蕴藏着造福人类健康的药物分子。